

April 04, 2019

BSE Limited
Corporate Relationship Department
1st floor, New Trading Ring
Rotunda Building, P J Towers
Dalal Street, Fort
Mumbai - 400 001

Sub: Amendment to Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI)

Dear Sir

We had in our earlier communications submitted to your good office that "Orchid Pharma Limited" ("the Company") is under Corporate Insolvency Resolution Process ("CIRP") vide order of the Honourable National Company Law Tribunal, Chennai Bench dated August 17, 2017. Pursuant to the above order, the powers of the Board of Directors stands suspended and the management of the affairs of the Company is vested with Shri Sripatham Venkatasubramanian Ramkumar, the Resolution Professional of the Company.

With reference to the subject matter and pursuant to Section 8(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations), we hereby notify that the Company has suitably amended the "Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information" and made effective the provisions of the PIT Regulations, as amended by Securities and Exchange Board of India (Prohibition of Insider Trading) (Amendment) Regulations, 2018. This updated Code of Practices and Procedures for Fair Disclosure of UPSI has been made available on the website of the Company i.e. www.orchidpharma.com

Kindly take the above on your records.

Thanking you,

Yours faithfully,



L Chandrasekar
Executive VP – Finance & Secretary